A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: guarantee (67), certify (28), warrant (16)

Finance and Performance Reports 2022-23 Month 2 May 2022

Description
Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose Issue to be addressed: Finance
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Finance-and-Performance-Reports-2022-23-Month-2-May-2022.pdf

Telephoning Results and Ranges

Description
University Hospital Southampton NHS Foundation Trust LABORATORY MEDICINE G3.2 Telephoning Results and Ranges G3.2 3
Url
/Media/UHS-website-2019/Docs/Services/Pathology/Lab-med/Telephoning-Results-and-Ranges.pdf

Finance and Performance Reports 2020-21 Month 4 July 2020

Description
2020/21 Finance Report - Month 4 Report to: Board of Directors and Finance & Investment Committee August 2020 Title: Fina
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2020/finance-and-performance-reports-2020-21-month-4-july-2020-1.pdf

Cytarabine1500

Description
Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA CYTARABINE (1500mg/m2) In-Patient Regimen Regimen • Acute Myeloid Leukaemia – In
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Cytarabine1500.pdf

Raising a concern or complaint - patient information

Description
Making a complaint means speaking up about something you are not happy with. If you choose to raise a concern or
Url
/Media/UHS-website-2019/Patientinformation/Contactingus/Raisingaconcernorcomplaint-2138-PIL.pdf

Afatinib Ver 1

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Regimen AFATINIB NSCLC - Afatinib Indication Treatment of locally
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/AfatinibVer1.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description
Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/kg)
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

Vinblastine Ver 1.1

Description
Chemotherapy Protocol LYMPHOMA VINBLASTINE Regimen Lymphoma – Vinblastine Indication Non-Hodgkin’s Lymphoma Hodgkin’s Lymphoma Toxicity Drug Vinblas
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Vinblastine-Ver-1.1.pdf

REPOCH (dose adjusted)-Cyclophosphamide-Doxorubicin-Etoposide-Prednisolone-Rituximab-Vincristine

Description
Chemotherapy Protocol LYMPHOMA REPOCH - CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONERITUXIMAB-VINCRISTINE (Dose adjusted regimen) There are multiple versions of this pro
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/REPOCH-dose-adjusted-Cyclophosphamide-Doxorubicin-Etoposide-Prednisolone-Rituximab-Vincristine.pdf

RCHOP(21)-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine (21) Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-RITUXIMAB-VINCRISTINE (21) (RCHOP 21) There are multiple versions of this protocol in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCHOP21-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine-21-Ver-1.2.pdf
401 to 410 of 1000
Previous … 39 40 41 42 43 … Next